BiotechTube

SHR-1210 + Gemcitabine + cis-platinum

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 29/100
29
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Nasopharyngeal Carcinoma

Conditions

Nasopharyngeal Carcinoma

Trial Timeline

Apr 26, 2017 → Jul 31, 2020

NCT ID
NCT03121716

About SHR-1210 + Gemcitabine + cis-platinum

SHR-1210 + Gemcitabine + cis-platinum is a phase 1 stage product being developed by Jiangsu Hengrui Medicine for Nasopharyngeal Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03121716. Target conditions include Nasopharyngeal Carcinoma.

What happened to similar drugs?

0 of 13 similar drugs in Nasopharyngeal Carcinoma were approved

Approved (0) Terminated (0) Active (13)
🔄CisplatinSun PharmaceuticalPhase 3
🔄Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
🔄5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
🔄CapecitabineSun PharmaceuticalPhase 3
🔄Nedaplatin + CisplatinSun PharmaceuticalPhase 3
🔄PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
🔄QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3

Hype Score Breakdown

Clinical
6
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT03121716Phase 1Completed

Competing Products

20 competing products in Nasopharyngeal Carcinoma

See all competitors
ProductCompanyStageHype Score
Nanatinostat + Valganciclovir + PembrolizumabViracta TherapeuticsPhase 1
11
Cisplatin 2 + Docetaxel + Cisplatin 1Sun PharmaceuticalPhase 2
31
CisplatinSun PharmaceuticalPhase 3
36
Cisplatin 1 + Cisplatin 2 + Docetaxel + XelodaSun PharmaceuticalPhase 3
36
5-fu + Lobaplatin + Placebo + leucogenSun PharmaceuticalPhase 3
47
CapecitabineSun PharmaceuticalPhase 3
36
Amifostine every-other-day regimen + Amifostine everyday regimenSun PharmaceuticalPhase 2
31
Nedaplatin + CisplatinSun PharmaceuticalPhase 3
40
PD-1 blocking antibody + Gemcitabine + Cisplatin (80 mg/m2) + Cisplatin (100 mg/m2) + CapecitabineSun PharmaceuticalPhase 3
47
QL1706 + Gemcitabine + CisplatinSun PharmaceuticalPhase 3
47
The combination treatment of anlotinib, penpulimab and capecitabine.Sun PharmaceuticalPhase 2
39
docetaxel, nedaplatin, and capecitabine + nedaplatin + docetaxel, cisplatin, and fluorouracil + cisplatin + docetaxel, cisplatin, and capecitabine + docetaxel, nedaplatin, and fluorouracilSun PharmaceuticalPhase 3
47
Pemetrexed (Alimta)Eli LillyPhase 2
35
Camrelizumab + Placebos + Gemcitabine + CisplatinJiangsu Hengrui MedicinePhase 3
36
Famitinib + CisplatinJiangsu Hengrui MedicinePhase 1
29
SHR-1701 + Gemcitabine + Cisplatin + Albumin PaclitaxelJiangsu Hengrui MedicinePhase 1
25
FamitinibJiangsu Hengrui MedicinePhase 2
35
ApatinibJiangsu Hengrui MedicinePhase 2
35
SHR-1210Jiangsu Hengrui MedicinePhase 2
35
SHR-1701 + FamitinibJiangsu Hengrui MedicinePhase 1/2
28